Eton Pharmaceuticals Stock (NASDAQ:ETON)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$15.40

52W Range

$3.25 - $21.48

50D Avg

$15.95

200D Avg

$13.92

Market Cap

$403.07M

Avg Vol (3M)

$482.48K

Beta

1.19

Div Yield

-

ETON Company Profile


Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

31

IPO Date

Nov 13, 2018

Website

ETON Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Product Sales and Royalties$38.51M$26.14M-
License$500.00K$5.50M-
Licensing Revenue--$10.00M

Fiscal year ends in Dec 24 | Currency in USD

ETON Financial Summary


Dec 24Dec 23Dec 22
Revenue$39.01M$31.64M$21.25M
Operating Income$-2.60M$-1.19M$-8.26M
Net Income$-3.82M$-936.00K$-9.78M
EBITDA$-2.60M$-291.00K$-6.49M
Basic EPS$-0.15$-0.04$-0.39
Diluted EPS$-0.15$-0.04$-0.39

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 13, 25 | 4:30 PM
Q4 24Mar 18, 25 | 10:00 AM
Q3 24Nov 12, 24 | 4:30 PM

Peer Comparison


TickerCompany
QTTBQ32 Bio Inc.
EYENEyenovia, Inc.
VRCAVerrica Pharmaceuticals Inc.
AQSTAquestive Therapeutics, Inc.
LRMRLarimar Therapeutics, Inc.
FENCFennec Pharmaceuticals Inc.